抗CTLA-4单克隆抗体治疗黑素瘤的进展

Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibodies in the treatment of malignant melanoma

恶性黑素瘤由于其侵袭性强，预后较差，目前在世界范围内仍是尚未攻克的难题之一。研究发现，抗CTLA-4单克隆抗体能显著提高黑素瘤患者平均生存期和客观有效率，是一种新型的依靠免疫作用的靶向治疗药物。这一研究指明干涉抑制性免疫调节点在肿瘤免疫治疗中具有重要作用，为晚期黑素瘤治疗研究提供了新的探索方向和治疗思路。

The treatment of malignant melanoma remains a difficult problem in the world because of its strong invasion and poor prognosis. It has been evidenced that anti-cytotoxic T-lymphocyte-associated antigen-4 （CTLA-4） monoclonal antibodies notably increase the average survival and objective response rate of patients with melanoma, and are considered to be a novel immune-based targeted therapeutic agent. The interference in inhibitory immune regulatory checkpoints has been demonstrated to play an important role in tumor immunotherapy, which may provide new directions and ideas for the treatment of advanced melanoma.